# The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis

> **NCT03643900** · NA · COMPLETED · sponsor: **First People's Hospital of Hangzhou** · enrollment: 618 (actual)

## Conditions studied

- Post-ERCP Pancreatitis
- Pancreatitis, Acute Necrotizing

## Interventions

- **DEVICE:** pancreatic duct stenting
- **DRUG:** rectal indomethacin

## Key facts

- **NCT ID:** NCT03643900
- **Lead sponsor:** First People's Hospital of Hangzhou
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-08
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-08-18
- **Target enrollment:** 618 (ACTUAL)
- **Last updated:** 2021-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03643900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03643900, "The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03643900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*